Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC）

Qian Chu500 enrolled

Overview

This observational study aims to construct and validate the performance of a multimodal predictive model in forecasting the outcomes of neoadjuvant therapy in patients with NSCLC. The core research question is: Can a multi-model approach predict outcomes of neoadjuvant therapy for non-small cell lung cancer and provide clinical recommendations?

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

NSCLC Neoadjuvant Therapy

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. pathologically diagnosed non-small cell lung cancer 2. The treatment plan is：receiving neoadjuvant chemo-immunotherapy during the study period, followed by surgical resection Exclusion Criteria: 1. recurrent or metastatic lung cancer; 2. patients with other primary tumors

Locations (2)

Tongji hospital

Wuhan, Hubei, China

RECRUITING

Sir Run Run Shaw Hospital

Hangzhou, Zhejiang, China

RECRUITING

Outcomes

Primary Outcomes

pathologic response

Time frame: Perioperative

Secondary Outcomes

EFS

event free survival

Time frame: One year after the treatment ended

Central Contacts

Minghao Hu

CONTACT

8613396366466 huminghao2010@126.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.